Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of February 2025, with the specific transaction date being February 27, 2025. The filing was submitted on February 28, 2025.
Key Financial Metrics and Transaction Details
The filing details a share repurchase executed as part of GSK's existing buyback programme. The transaction was conducted through Citigroup Global Markets Limited on the London Stock Exchange (XLON).
- Shares Purchased: 800,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,446.50p; highest price paid was 1,464.00p.
- Volume-Weighted Average Price (VWAP): 1,458.36p.
- Treasury Shares Held: Following this purchase, GSK holds 172,481,355 ordinary shares in treasury.
- Shares in Issue: 4,142,685,716 ordinary shares (excluding treasury shares).
- Total Voting Rights: 4,142,685,716.
The filing does not provide data on revenue, profit, cash flow, margins, or debt levels, as this document is strictly a disclosure of a share buyback transaction.
Material Changes and Programme Progress
This purchase was effected pursuant to a non-discretionary agreement entered into with the broker on February 24, 2025. Since the commencement of this specific agreement on February 24, 2025, the company has purchased an aggregate of 3,411,052 ordinary shares. The purchased shares are held as Treasury shares.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, operational outlook, or management commentary regarding business performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's Annual Report on Form 20-F for 2023 and Q4 Results for 2024.
Investor Verification Checklist
- Verify the total number of treasury shares held (172,481,355) against the company's latest capital structure disclosures.
- Confirm the remaining capacity under the existing buyback programme, as this filing only details purchases since February 24, 2025.
- Review the "Risk factors" section in the 2023 Form 20-F and Q4 2024 results for context on the forward-looking statement disclaimer.
- Check the total voting rights denominator (4,142,685,716) for compliance with FCA Disclosure Guidance and Transparency Rules.